<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561492</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0289</org_study_id>
    <nct_id>NCT04561492</nct_id>
  </id_info>
  <brief_title>Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment</brief_title>
  <acronym>PentiMyelo</acronym>
  <official_title>Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to confirm the relevance of PET using [68Ga]Ga -PentixaFor ligand, in&#xD;
      comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple&#xD;
      myeloma patients in first line treatment. The prognostic value of positive CXCR4 expression&#xD;
      will also be assessed and [68Ga]Ga -PentixaFor/FDG discordances explored.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.</measure>
    <time_frame>1 Month</time_frame>
    <description>Sensitivity will be assessed by patient and lesion analysis by defining:&#xD;
True positive (TP):&#xD;
lesion positive with [68Ga]Ga-PentixaFor-PET and positive by FDG-PET&#xD;
or lesion positive with [68Ga]Ga-PentixaFor-PET, negative on FDG-PET but confirmed by another CT scan/ MRI or histology, or confirmed by follow-up (until therapeutic evaluation).&#xD;
False negative (FN): - lesion negative with [68Ga]Ga-PentixaFor-PET and positive by FDG-PET and confirmed by CT or MRI or histology, or confirmed by follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis, the specificity, the positive predictive value (PPV) and negative predictive value (NPV) of [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>1 Month</time_frame>
    <description>The specificity (PPV and NPV) of [68Ga]Ga-PentixaFor-PET at the time of initial diagnosis will be assessed by patient and lesion analysis using the same definitions of TP and FN as for the primary objective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the prognostic impact of FDG PET and of [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique</measure>
    <time_frame>1 Month</time_frame>
    <description>The prognostic impact of PET-FDG and [68Ga]Ga-PentixaFor-PET based on the number of lesions detected and their intensity of uptake by each imaging technique will be evaluated by assessing the impact of these data on the PFS and OS. PFS is defined as the time from the start of treatment to relapse or progression. OS is defined as the time from the start of first treatment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>1 Month</time_frame>
    <description>Investigators will consider as discordant a lesion positive by FDG PET but negative by [68Ga]Ga-PentixaFor-PET and/or a lesion negative by FDG PET but positive by [68Ga]Ga-PentixaFor-PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the factors associated with discrepancies between FDG PET and [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>1 Month</time_frame>
    <description>Investigators will consider as discordant a lesion positive by FDG PET but negative by [68Ga]Ga-PentixaFor-PET and/or a lesion negative by FDG PET but positive by [68Ga]Ga-PentixaFor-PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the correlation between PET-FDG and [68Ga]Ga-PentixaFor-PET uptakes evaluated by SUV and the cytogenetic data evaluated on the myelogram (particularly the measurement of the expression of the gene coding</measure>
    <time_frame>1 Month</time_frame>
    <description>68Ga]Ga -PentixaFor and FDG uptakes assessed by SUV and the quantitative expression of biological markers on myelogram (including expression of the gene coding for hexokinases).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>1 Month</time_frame>
    <description>Tolerance of [68Ga]Ga-PentixaFor will be assessed by clinical monitoring of the patient for 1 hour after [68Ga]Ga-PentixaFor injection. Clinical data (heart rate, respiratory rate and blood pressure) will be collected prior [68Ga]Ga -PentixaFor injection before acquisition (at 60 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>1 Month</time_frame>
    <description>Tolerance of [68Ga]Ga-PentixaFor will be assessed by clinical monitoring of the patientat the end of acquisition (at approximately 80 min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of therapeutic evaluation the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET and if available their link with histology.</measure>
    <time_frame>100 Day or 6 Month</time_frame>
    <description>Investigators will consider as discordant a lesion positive by FDG PET but negative by [68Ga]Ga-PentixaFor-PET and/or a lesion negative by FDG PET but positive by [68Ga]Ga-PentixaFor-PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.</measure>
    <time_frame>100 Day and 6 Month</time_frame>
    <description>The prognostic impact of [68Ga]Ga-PentixaFor-PET after therapy will be determined by evaluating the impact of a decrease uptake and/or a normalisation of images on PFS and OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.</measure>
    <time_frame>Every 6 months after the end of treatment</time_frame>
    <description>The prognostic impact of [68Ga]Ga-PentixaFor-PET after therapy will be determined by evaluating the impact of a decrease uptake and/or a normalisation of images on PFS and OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of therapeutic evaluation the link between PET-FDG, [68Ga]Ga-PentixaFor-PET results and minimal residual disease evaluated by flow cytometry</measure>
    <time_frame>100 Day or 6 Month</time_frame>
    <description>PET-FDG, [68Ga]Ga-PentixaFor-PET results (positive/negative) and minimal residual disease evaluated by flow cytometry (positive/negative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine at the time of therapeutic evaluation the tolerance of [68Ga]Ga-PentixaFor-PET</measure>
    <time_frame>100 Day or 6 Month</time_frame>
    <description>Tolerance of [68Ga]Ga-PentixaFor will be assessed by clinical monitoring of the patient for 1 hour after [68Ga]Ga -PentixaFor injection. Clinical data (heart rate, respiratory rate and blood pressure) will be collected prior [68Ga]Ga-PentixaFor injection before acquisition (at 60 min) and at the end of acquisition (at approximately 80 min).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>[68Ga]Ga-PentixaFor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]Ga-PentixaFor</intervention_name>
    <description>Tomography by emission of positons (PET) with theradiopharmaceutic [68Ga]Ga-PentixaFor</description>
    <arm_group_label>[68Ga]Ga-PentixaFor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Symptomatic MM patients according to IMWG criteria (12) requiring first-line treatment&#xD;
&#xD;
          -  MM with disease measurable either by serum evaluation of the monoclonal component or&#xD;
             by free light chain assay (serum or urinary)&#xD;
&#xD;
          -  Written and signed informed consent (obtained on the screening day at the latest and&#xD;
             before any investigation)&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) &lt; 2&#xD;
&#xD;
          -  Patient affiliated to or beneficiary of the National Health Service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive, active Hepatitis B or C&#xD;
&#xD;
          -  Childbearing or child breast feeding women&#xD;
&#xD;
          -  Women or men without effective contraceptive barrier if needed&#xD;
&#xD;
          -  Respiratory insufficiency defined as DLCO &lt;40% of the corrected value&#xD;
&#xD;
          -  eGFR &lt; 50 ml/min by MDRD or CKDEPI&#xD;
&#xD;
          -  Previous or concurrent second malignancy except for adequately treated basal cell&#xD;
             carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively&#xD;
             treated solid cancer, with no evidence of disease for at least 2 years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Known active infection&#xD;
&#xD;
          -  Patient with uncontrolled insulin-dependent or non-insulin-dependent diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caroline Bodet Milin, MD, PhD</last_name>
    <phone>0033240084143</phone>
    <email>caroline.milin@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes UH</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Bodet-Milin, MD, PhD</last_name>
      <email>caroline.milin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Bodet Milin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

